IRIS
ZANARDI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.842
Totale 4.842
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.842
Totale 4.842
Salva come PNG Salva come JPEG
Città #
Genova 3.368
Rapallo 699
Genoa 558
Vado Ligure 209
Bordighera 8
Totale 4.842
Salva come PNG Salva come JPEG
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 156
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 151
A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature 141
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 134
Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. 132
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 129
Combinations of hormonal therapy and chemotherapy 122
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 119
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 118
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 118
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 114
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 111
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 111
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 109
Bone metastases from prostate cancer: hormonal therapy 108
May adjuvant therapy play a role for the management of renal cell carcinoma? A review of literature and ongoing trials 107
Better Together: Targeted Combination Therapies in Breast Cancer 107
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 105
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 105
Patients Treated with Rituximab-Containing Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to Influenza Vaccine Associated with a Persistent Depletion of B Memory Cells 103
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 102
Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey 99
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 97
Treatment of elderly patients with metastatic renal cell carcinoma 96
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 95
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era 89
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 88
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 85
To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone 85
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study 83
First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO) adjuvant trastuzumab 82
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study 81
861P Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders 79
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes 78
Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma 74
Better Together: Immunotherapy as Future Combination Strategy for Breast Cancer 72
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer 71
First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease 71
Insights from a long-term follow-up evaluation of early breast cancer (BC) outcomes by tumor subtype (TS) 70
Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience 68
EFFICACY AND SAFETY OF SUNITINIB AND EVEROLIMUS AS FRONTLINE TREATMENT FOR NON-CC-RCC: A POOLED-ANALYSIS FROM RANDOMIZED TRIALS 65
Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival 65
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases 65
HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature 64
Long-term results from INT-HER study: Retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patients—Single institution experience 60
Baseline 18F-Fluoride PET-derived parameters predict modification of toxicity-and response-related blood biomarkers in prostate cancer patients treated with 223Ra-Dichloride: preliminary results 59
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 55
Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer 53
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer 48
Combination therapy in metastatic renal cell carcinoma: Back to the future? 48
Real-world survival improvements in patients with newly diagnosed metastatic prostate cancer treated in the United States 47
Management of advanced endometrial cancer 44
null 40
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223 38
Neoplasie prostatiche 33
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial 33
SUNITINIB IN METASTATIC RENAL CELL CARCINOMA: RESULTS OF A MONOCENTRIC EXPERIENCE 32
Role of FDG PET/CT in the prognostic stratification and response assessment of castration-resistant prostate cancer treated with radium-223 dichloride 31
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives 31
Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management 28
Cardiac Metastasis from Prostate Cancer: A Case Study Underlying the Crucial Role of the PSMA PET/CT 20
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients 17
Totale 5.041
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.485
article - articoli 17.210
book - libri 0
conference - conferenze 290
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 985
Totale 36.970
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.482 0 0 0 100 173 227 263 137 155 230 155 42
2020/2021586 32 47 33 78 55 47 17 61 30 82 48 56
2021/2022720 23 24 39 75 29 74 15 149 76 78 43 95
2022/2023796 59 83 12 78 145 129 0 65 129 5 81 10
2023/2024458 13 57 11 58 28 87 24 28 22 28 30 72
2024/2025226 37 89 45 55 0 0 0 0 0 0 0 0
Totale 5.041